Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Investor Presentation (March 2024)
24 slides from Marinomed Biotech's investor presentation, March 2024
Slide 1: Marinomed Biotech AG Corporate Presentation
Marinomed Biotech AG Corporate Presentation March 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Contents
Contents 1. Company 4 2. Platforms, Pipeline 9 3. Financials 17 4. Outlook 20 © Marinomed Biotech AG 3
Slide 4: Company
Company Overview, Business Model, Equity Story © Marinomed Biotech AG
Slide 5: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria Launch of first Invention of Marinosolv New headquarter in Deal with Procter & Carragelose product solubilization technology Korneuburg Gamble 2008 2016 2020 2022 2006 2011 2019 2021 2023 Foundation as spi
Slide 6: Business Model
Business Model Lean organization & growing existing business RESEARCH & DEVELOPMENT SALE OF GOODS Research & Pre-clinical Early clinical Supply chain Innovation development development organization Intellectual property High-value products Revenue through license deals Revenue through (upfront, mile
Slide 7: Equity Story
Equity Story Solid existing business, continued growth perspective through late-stage pipeline assets • Experienced management team • Solid revenue from marketed product portfolio • Three key assets in partnering: • Carragelose portfolio • Budesolv • Tacrosolv • Lean and efficient business model: co
Slide 8: Platforms, Pipeline
Platforms, Pipeline © Marinomed Biotech AG
Slide 9: Platforms
Platforms • Polymer extracted from red seaweed • Solubilization of poorly water-soluble compounds • Forms non-specific layer that protects mucosa from viruses & • Significantly increases bioavailability allergens → multi-purpose • Allows dose reduction & faster onset of action • Favorable safety pro
Slide 10: Platforms & Therapeutic Areas
Platforms & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & Allergy Eye drops Budesolv Tacrosolv Solv4U cold portfolio nasal spray Dry, irritated eyes A
Slide 11: Pipeline
Pipeline Including late-stage projects with low risk and meaningful upside potential Pharmaceutical Products Therapeutic Product Status Pre-clinical Phase I Phase II Phase III Filing Area Indication MAM-1004-1/Budesolv Filing in Treatment of severe allergic rhinitis preparation IMMUNOLOGY MAM-1003-1
Slide 12: Carragelose®
Carragelose® Protective layer against viruses and allergens – multi-use potential Viral respiratory diseases Carragelose Eye care • Broadly-active against several • Carragelose has excellent respiratory viruses moisturizing properties • Clinically validated1 • Eye drops can provide relief of dry eye
Slide 13: Budesolv, anti-allergic product post phase III
Budesolv, anti-allergic product post phase III Budesonide fully solubilized with Marinosolv® - fast-acting symptom relief after first dose Budesolv: Competitors: Clear Suspensions Budesolv Positioning Solution Improved local tolerability Preservatives none always higher patient acceptance Onset of a
Slide 14: Budesolv development: preparations for approval
Budesolv development: preparations for approval Technical problems solved – new IP generated Budesolv stability New formulation Regulatory Submission for issues consequences approval Slight change in Study medication composition, new Pharmacokinetic Country-dependent unstable secondary study & produ
Slide 15: Tacrosolv
Tacrosolv Best-in-class macrolide immunosuppressant – fully solubilized with Marinosolv® Fully solubilized Tacrolimus Tacrolimus (FK506) Tacrosolv • Immunosuppressant widely used systemically after • Fully solubilized Tacrolimus organ transplantation • Better bioavailability than suspensions (such a
Slide 16: Solv4U overview
Solv4U overview Solubilization technology partnerships based on Marinosolv® PHASE I PHASE II PHASE III PHASE IV FEASIBILITY FORMULATION PRECLINICAL & TECH TRANSFER DEVELOPMENT CLINICAL STUDIES Enhanced solubility of target Optimize formulation & Target Product Profile (TPP) & Enable manufacturing at
Slide 17: Financials
Financials Q3 2023, preliminary revenue FY 2023 © Marinomed Biotech AG
Slide 18: Post-pandemic slow-down results in declining sales
Post-pandemic slow-down results in declining sales High customer stock-levels lead to slow order intake Y-o-Y comparison of quarterly revenues (m€) Comments Historical numbers 11.3 9.2 • Revenues expectedly declined to €9.2m (previous year €11.3m) • Revenues largely related to Carragelose product po
Slide 19: Stabilized cash situation
Stabilized cash situation Low cash drain due to Carragelose revenues and inflows from convertible bond program • Ended December 2022 with €8.2m in cash • Raised +€0.5m through convertible note funding program • Earned +€3.2m net cash through profitable sale of goods and licensing contracts • Repaid
Slide 20: Outlook
Outlook © Marinomed Biotech AG
Slide 21: Project status updates
Project status updates Project Status/next steps MAM-1004-1/Budesolv Work on registration with Luoxin for Greater China; additional partnership in 2024 Immunology MAM-1003-1/Tacrosolv Late-stage clinical development - enable first partnership MAM-1001-4 nasal spray Launch in 2024; drive BD-process M
Slide 22: Near-term targets and plan for 2024
Near-term targets and plan for 2024 Focus on reduction of cash burn and completion of business development deals Carragelose® OTC business • US FDA approval with Procter & Gamble • Evaluate strategic options for Carragelose business unit Commercialization of Marinosolv® key assets • Additional partn
Slide 23: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2024 April 16, 2024 Publication of the Annual Report 2023 May 22, 2024 Publication of the Results Q1 2024 Record Date for participation June 10, 2024 at the Annual General Meeting June 20, 2024 7th Annual General Meeting August 20, 2024 Publication
Slide 24: www.marinomed.com
www.marinomed.com 0) Marinomed
Marinomed Biotech — Investor Presentation (March 2024) on 6ix